University of California San Francisco

Methotrexate toxicity induced by ciprofloxacin leading to psoriatic plaque ulceration: a case report. (24153144)

Kamangar F, Berger TG, Fazel N, Koo JY PMID: 24153144

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. (23982177)

Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH PMID: 23982177

An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis. (23855593)

Gupta R, Levin E, Wu JJ, Koo J, Liao W PMID: 23855593

An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis. (23855593)

Gupta R, Levin E, Wu JJ, Koo J, Liao W PMID: 23855593

Biologic fatigue in psoriasis. (23875537)

Levin EC, Gupta R, Brown G, Malakouti M, Koo J PMID: 23875537

Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome. (24033633)

Braunstein I, Wanat KA, Abuabara K, McGowan KL, Yan AC, Treat JR PMID: 24033633

Ten-year publication trends in dermatology in mainland China. (23968296)

Xin S, Mauro JA, Mauro TM, Elias PM, Man MQ PMID: 23968296

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. (23890088)

Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC PMID: 23890088

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. (23890088)

Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC PMID: 23890088

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. (23890088)

Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC PMID: 23890088